| Literature DB >> 32202140 |
Feifei Yang1,2, Lina Han1, Na Zhao1, Yang Yang2, Di Ge1, Hua Zhang1, Yihua Chen2.
Abstract
Aim: Histone deacetylases (HDACs) are one of the validated targets for cancer treatments. In our previous work, we designed a series of bis-substituted aromatic amide HDAC inhibitors (HDACis), among which compounds 7 and 8 showed promising anticancer effects. However, the low solubilities prevented their subsequent developments. We developed additional thiophene-based hydroxamate HDACis in order to improve their physicochemical properties. Materials & methods: In vitro biological evaluations of these analogs revealed potent antiproliferative and antimigrated activities. More importantly, compound 10h exhibited excellent in vivo antitumor activities in MDA-MB-231 xenograft model mice. Furthermore, 10h showed better anticancer activities and drug-like properties than 7. Results & conclusion: Our results proved that thiophene-based hydroxamate HDACis can serve as a promising framework for developing potential anticancer agents.Entities:
Keywords: antimetastatic; antiproliferative; bis-substituted aromatic amide; histone deacetylase inhibitors; structure–activity relationship
Mesh:
Substances:
Year: 2020 PMID: 32202140 DOI: 10.4155/fmc-2019-0343
Source DB: PubMed Journal: Future Med Chem ISSN: 1756-8919 Impact factor: 3.808